These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21539743)

  • 1. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm.
    Albrich WC; Dusemund F; Rüegger K; Christ-Crain M; Zimmerli W; Bregenzer T; Irani S; Buergi U; Reutlinger B; Mueller B; Schuetz P
    BMC Infect Dis; 2011 May; 11():112. PubMed ID: 21539743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections.
    Schuetz P; Wolbers M; Christ-Crain M; Thomann R; Falconnier C; Widmer I; Neidert S; Fricker T; Blum C; Schild U; Morgenthaler NG; Schoenenberger R; Henzen C; Bregenzer T; Hoess C; Krause M; Bucher HC; Zimmerli W; Mueller B;
    Crit Care; 2010; 14(3):R106. PubMed ID: 20529344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections.
    Albrich WC; Rüegger K; Dusemund F; Bossart R; Regez K; Schild U; Conca A; Schuetz P; Sigrist T; Huber A; Reutlinger B; Müller B
    Swiss Med Wkly; 2011; 141():w13237. PubMed ID: 21805408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
    Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
    Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
    Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
    Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
    Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study.
    Odermatt J; Meili M; Hersberger L; Bolliger R; Christ-Crain M; Briel M; Bucher HC; Mueller B; Schuetz P
    BMC Cardiovasc Disord; 2017 Jul; 17(1):178. PubMed ID: 28676115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Proadrenomedullin Enhanced CURB65 Score Algorithm in Patients with Community-Acquired Pneumonia in "Real Life", an Observational Quality Control Survey.
    Widmer D; Drozdov D; Rüegger K; Litke A; Arici B; Regez K; Guglielmetti M; Schild U; Conca A; Schäfer P; Kouegbe RB; Reutlinger B; Blum C; Schuetz P; Irani S; Huber A; Bürgi U; Müller B; Albrich WC
    J Clin Med; 2014 Mar; 3(1):267-79. PubMed ID: 26237261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
    Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
    PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections.
    Baumann P; Fuchs A; Gotta V; Ritz N; Baer G; Bonhoeffer JM; Buettcher M; Heininger U; Szinnai G; Bonhoeffer J;
    PLoS One; 2022; 17(3):e0264305. PubMed ID: 35271609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center.
    Benedetti I; Spinelli D; Callegari T; Bonometti R; Molinaro E; Novara E; Cassinari M; Frino C; Guaschino R; Boverio R; Lauritano EC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1743-1751. PubMed ID: 33629344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
    Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
    Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
    Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
    Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midregional proadrenomedullin safely reduces hospitalization in a low severity cohort with infections in the ED: a randomized controlled multi-centre interventional pilot study.
    Gonzalez Del Castillo J; Clemente-Callejo C; Llopis F; Irimia A; Oltra-Hostalet F; Rechner C; Schwabe A; Fernandez-Rodriguez V; Sánchez-Mora C; Giol-Amich J; Prieto-García B; Bardés-Robles I; Ortega-de Heredia MD; García-Lamberechts EJ; Navarro-Bustos C;
    Eur J Intern Med; 2021 Jun; 88():104-113. PubMed ID: 33906810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.